Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q4 EPS of ($0.35), $0.04 worse than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.